Journal Article

Randomized trial to evaluate the safety, tolerability, and immunogenicity of a booster (third dose) of BNT162b2 COVID-19 vaccine coadministered with 20-valent pneumococcal conjugate vaccine in adults ≥65 years old

Fitz-Patrick, David, Belanger, Todd, Belanger, Kelly, Watson, Wendy, Yacisin, Kari, McElwee, Kathleen, Young, Mariano, Gruber, William C., Lee, Dung-Yang, Peng, Yahong, Scott, Daniel A.

2023

Overview

•Study evaluated BNT162b2 booster given with PCV20 or separately in adults ≥65 years.•Safety profiles were acceptable in all groups.•Immune responses to BNT162b2 + PCV20 were similar to separate administration. Older adults are at increased risk of adverse outcomes from pneumococcal disease and COVID-19. Vaccination is an established strategy for preventing both illnesses. This study evaluated the safety and immunogenicity of coadministration of the 20-valent pneumococcal conjugate vaccine (PCV20) and a booster (third dose) of BNT162b2 COVID-19 vaccine. This phase 3, randomized, double-blind, multicentre study included 570 participants aged ≥65 years randomized 1:1:1 to PCV20 and BNT162b2 coadministered, or PCV20 or BNT162b2 only (administered with saline for blinding). Primary safety endpoints included local reactions, systemic events, adverse events (AEs) and serious AEs (SAEs). Secondary objectives were immunogenicity of PCV20 and BNT162b2 when administered together or separately. Coadministration of PCV20 and BNT162b2 was well tolerated. Local reactions and systemic events were generally mild-moderate; injection-site pain and fatigue were the most frequent local and systemic events, respectively. AE and SAE rates were low and similar across groups. No AEs led to discontinuation; no SAEs were considered vaccination-related. Robust immune responses were observed, with opsonophagocytic activity geometric mean fold rises (GMFRs; from baseline to 1 month) of 2.5–24.5 and 2.3–30.6 across PCV20 serotypes in Coadministration and PCV20-only groups, respectively. GMFRs for full-length S-binding IgG of 35.5 and 39.0, and for neutralizing titres against SARS-CoV-2-wild type virus of 58.8 and 65.4, were observed in the Coadministration and BNT162b2-only groups, respectively. Safety and immunogenicity of coadministered PCV20 and BNT162b2 were similar to those of PCV20 or BNT162b2 administered alone, suggesting that the 2 vaccines may be coadministered. Trial Registration:ClinicalTrials.gov, NCT04887948.

• Publisher: Elsevier Ltd,Elsevier Limited,Elsevier Science
• Subject: 20-valent pneumococcal conjugate vaccine / Adults / Allergy and Immunology / Coadministration / Conjugates / COVID-19 / COVID-19 infection / COVID-19 vaccines / Hypothesis testing / Immune response / Immunogenicity / Immunoglobulin G / injection site / International organizations / Mortality / Objectives / Older people / pain / Pneumonia / risk / Safety / SARS-CoV-2 / Serotypes / Severe acute respiratory syndrome coronavirus 2 / Statistical analysis / Streptococcus infections / Streptococcus pneumoniae / vaccination / Vaccines / Viral diseases / viruses